{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T14:25:29Z","timestamp":1793111129992,"version":"4.5.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"7-8","license":[{"start":{"date-parts":[[2015,1,17]],"date-time":"2015-01-17T00:00:00Z","timestamp":1421452800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1007\/s00508-014-0692-4","type":"journal-article","created":{"date-parts":[[2015,1,16]],"date-time":"2015-01-16T05:26:53Z","timestamp":1421386013000},"page":"256-261","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["N-acetylcysteine in patients with COPD exacerbations associated with increased sputum","N-Acetylcystein bei Patienten mit Exazerbation einer COPD mit erh\u00f6hter Sputumproduktion"],"prefix":"10.1007","volume":"127","author":[{"given":"Zeynep","family":"Ayfer Aytemur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aysegul","family":"Baysak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozer","family":"Ozdemir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timur","family":"K\u00f6se","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Sayiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,1,17]]},"reference":[{"key":"692_CR1","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1183\/09031936.00102509","volume":"34","author":"PW Jones","year":"2009","unstructured":"Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and first validation of the COPD assessment test. Eur Respir J. 2009;34:648\u201354.","journal-title":"Eur Respir J"},{"key":"692_CR2","doi-asserted-by":"crossref","unstructured":"Kim V, Garfield JL, Grabianowski CL, Krahnke JS, Gaughan JP, Jacobs MR, Criner GJ. The effect of chronic sputum production on respiratory symptoms in severe COPD. COPD 2011;8:114\u201320.","DOI":"10.3109\/15412555.2011.558546"},{"key":"692_CR3","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1053\/rmed.2001.1066","volume":"95","author":"M Kasielski","year":"2001","unstructured":"Kasielski M, Nowak D. Long-term administration of N-acetylcysteine decreases hydrogen peroxide exhalation in subjects with chronic obstructive pulmonary disease. Respir Med 2001;95:448\u201356.","journal-title":"Respir Med"},{"key":"692_CR4","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1183\/09031936.03.00039602","volume":"21","author":"S Blesa","year":"2003","unstructured":"Blesa S, Cortijo J, Mata M, Serrano A, Closa D, Santangelo F, Estrela JM, Suchankova J, Morcillo EJ. Oral N-acetylcysteine attenuates the rat pulmonary inflammatory response to antigen. Eur Respir J 2003;21:394\u2013400.","journal-title":"Eur Respir J"},{"key":"692_CR5","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/S0140-6736(05)66456-2","volume":"365","author":"M Decramer","year":"2005","unstructured":"Decramer M, Rutten-van M\u00f6lken M, Dekhuijzen PN, Troosters T, van Herwaarden C, Pellegrino R, van Schayk CP, Olivieri D, Del Donno M, De Backer W, Lankhorst I, Ardia A. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomized placebo-controlled trial. Lancet. 2005;365:1552\u201360.","journal-title":"Lancet"},{"key":"692_CR6","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2466-4-13","volume":"4","author":"PN Black","year":"2004","unstructured":"Black PN, Morgan-Day A, McMillan TE, Poole PJ, Young RP. Randomised, controlled trial of N-acetylcysteine for treatment of acute exacerbations of chronic obstructive pulmonary disease. BMC Pulm Med. 2004;4:13.","journal-title":"BMC Pulm Med"},{"key":"692_CR7","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1164\/ajrccm\/136.5.1285","volume":"136","author":"American Thoracic Society","year":"1987","unstructured":"American Thoracic Society: Standardized lung function testing: 1987 Update, Am Rev Respir Dis. 1987;136:1285\u201398","journal-title":"Am Rev Respir Dis"},{"issue":"5","key":"692_CR8","first-page":"40","volume":"16","author":"PH Quanjer","year":"1993","unstructured":"Quanjer PH, Tammeling GJ, Cotes JE, Pederson OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report working party standardization of lung function tests, European community for steel and coal. Official statement of the European respiratory society. Eur Respir J Suppl. 1993;16:40.","journal-title":"Eur Respir J Suppl"},{"issue":"suppl","key":"692_CR9","first-page":"A489","volume":"161","author":"FSF Ram","year":"2000","unstructured":"Ram FSF, Poole PJ, Bagg W, Stewart J, Black PN. Randomised, controlled trial of theophylline for the treatment of exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;161(suppl):A489","journal-title":"Am J Respir Crit Care Med"},{"key":"692_CR10","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1164\/ajrccm.153.5.8630597","volume":"153","author":"J Vestbo","year":"1996","unstructured":"Vestbo J, Prescott E, Lange P. Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. Am J Respir Crit Care Med. 1996;153:1530\u20135","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"692_CR11","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1183\/09031936.95.08081333","volume":"8","author":"E Prescott","year":"1995","unstructured":"Prescott E, Lange P, Vestbo J. Chronic mucus hypersecretion in COPD and death from pulmonary infection. Eur Respir J. 1995;8:1333\u20138","journal-title":"Eur Respir J"},{"key":"692_CR12","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1378\/chest.10-2948","volume":"140","author":"V Kim","year":"2011","unstructured":"Kim V, Han MK, Vance GB, Make BJ, Newell JD, Hokanson JE, Hersh CP, Stinson D, Silverman EK, Criner GJ, COPDGene Investigators. The chronic bronchitic phenotype of COPD: an analysis of the COPDGene Study. Chest. 2011;140:626\u201333.","journal-title":"Chest"},{"key":"692_CR13","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1080\/15412550600977361","volume":"3","author":"ER Sutherland","year":"2006","unstructured":"Sutherland ER, Crapo JD, Bowler RP. N-acetylcysteine and exacerbations of chronic obstructive pulmonary disease. COPD. 2006;3:195\u2013202.","journal-title":"COPD"},{"key":"692_CR14","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1183\/09059180.00003610","volume":"19","author":"M Decramer","year":"2010","unstructured":"Decramer M, Janssens W. Mucoactive therapy in COPD. Eur Respir Rev. 2010;19:134\u201340.","journal-title":"Eur Respir Rev"},{"key":"692_CR15","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1016\/S0140-6736(08)60869-7","volume":"371","author":"JP Zheng","year":"2008","unstructured":"Zheng JP, Kang J, Huang SG, Chen P, Yao WZ, et al. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomize placebo-controlled study. Lancet. 2008;371:2013\u20138","journal-title":"Lancet"},{"issue":"6","key":"692_CR16","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2165\/00044011-200525060-00005","volume":"25","author":"R Zuin","year":"2005","unstructured":"Zuin R, Palamidese A, Negrin R, Catozzo L, Scarda A, Balbinot M. High-dose N-acetylcysteine in patients with exacerbations of chronic obstructive pulmonary disease. Clin Drug Investig. 2005;25:401\u20138.","journal-title":"Clin Drug Investig"}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-014-0692-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00508-014-0692-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-014-0692-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T21:58:53Z","timestamp":1559080733000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00508-014-0692-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1,17]]},"references-count":16,"journal-issue":{"issue":"7-8","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["692"],"URL":"https:\/\/doi.org\/10.1007\/s00508-014-0692-4","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"value":"0043-5325","type":"print"},{"value":"1613-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1,17]]}}}